Ann: Quarterly update and Appendix 4C, page-25

Covid the opportunity to show their product. Provide additional revenue. STD approval be the game changer, look at the numbers and do the maths. Only need a tiny fraction of what will be a very very large market. I find it interesting that so many look at the covid testing only ,yet the majority invested pre covid 19 being heard of. Sales over last 6 months obviously show the product ain’t too shabby and can be easily modified to suit. Imagine once all approvals given, be fingers in many pies. Meanwhile covid just keeps on giving. Don’t think no vaccine just around the corner. Easy 4 quarters of testing in front of us if not more